Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)

NCT07931573 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07931573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 10, 2026
Completion date
August 8, 2028
Enrollment
1,200 (estimated)
Sites
230

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes

Arms

As registered; 3 arms.

  • Zenagamtide ExperimentalZenagamtide

    Participants will receive zenagamtide subcutaneously once weekly

  • Semaglutide Active comparatorSemaglutide

    Participants will receive semaglutide subcutaneously once weekly

  • Placebo Placebo comparatorPlacebo

    Participants will receive placebo matched to semaglutide or zenagamtide subcutaneously once weekly

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in glycated haemoglobin (HbA1c) [non-inferiority] From baseline (week 0) to week 60

    Measured in percentage point

Lead sponsor's other trials

Novo Nordisk A/S, most recent start first.

Similar trials

Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.